Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant respiratory safety in mild-moderate OSA
NCT03765294Phase 1Completed
- Sponsor
- Idorsia
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Insomnia comparing Daridorexant 50 mg with Placebo (2 arms). Primary endpoint: Apnea/Hypopnea Index after multiple-dose administration at Day 5. Started Mar 2019; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03765294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765294.